Introduction
Vascular endothelial growth factor (VEGF) 1 (1)/vascular permeability factor (VPF) (2, 3) is a potent endothelial cell mitogen in vitro (1, 3) and a potent permeability mediator (2, 3) and angiogenic growth factor in vivo (3, 4) . VEGF/VPF, hereafter referred to as VEGF, is a homodimeric glycoprotein found as four isoforms, generated by alternative splicing from a single gene (5) . Two specific VEGF receptors located exclusively on endothelial cells (ECs) have been identified to date. They are KDR (6) and flt-1 (7), both tyrosine-kinases that autophosphorylate in response to VEGF stimulation (6) (7) (8) .
VEGF appears to play a role in hypoxia-related angiogenesis occurring during wound healing (9) , proliferative retinopathy (10) , revascularization of ischemic areas (11, 12) and tumor progression (13) (14) (15) (16) . In addition to hypoxia-induced expression of VEGF (13, 17, 18) , various investigators have also documented in vivo increased expression of its receptors in pathologic conditions characterized by hypoxia. For example, ECs of tumor vessels but not of normal tissues, express VEGF receptors (14) (15) (16) . Although a solid neoplasm is richly vascularized, the combination of rapid tumor growth and interstitial edema due to the highly permeable vasculature result in conditions of local hypoxia (19, 20) . Increased production of VEGF by keratinocytes during wound healing (9) also parallels increased expression of VEGF receptors on neovessels of healing wounds (21) . Interestingly, low oxygen tension characterizes the central portion of a wound, due to disruption of the local vasculature (22) . Furthermore, systemic administration of VEGF in a rabbit ischemic hindlimb model, causes selective revascularization of the ischemic but not of the normally vascularized areas of the limb (23) . The localized biological effects observed in this experimental model imply that local expression of VEGF receptors might be increased. All these findings suggest that hypoxia-dependent local factors might regulate angiogenesis not only via induction of VEGF, but also via concomitant induction of specific VEGF receptors on ECs, therefore selectively targeting maximal angiogenesis to oxygen deprived areas.
To test this hypothesis, we evaluated the effects of low oxygen tension on binding of recombinant human I-VEGF to ECs was due to increased number of KDR receptors expressed by these cells, rather than to a change in the receptor's affinity.
These data indicate that ischemic tissues may release and/ or produce soluble "factor(s)" capable of locally upregulating VEGF receptor expression on ECs and thereby promote local neovascularization. These observations extend the conceptual basis for mechanisms which control hypoxia-dependent angiogenesis.
Methods
Reagents. All reagents used were obtained from Sigma Chemical Co. (St. Louis, MO), unless otherwise stated. Human recombinant basic fibroblast growth factor (bFGF) and platelet derived growth factor BB (PDGF BB) were obtained from Genzyme Corp. (Cambridge, MA).
Cell culture. Human umbilical vein (HUV) ECs were isolated according to the method of Jaffe et al. (24) , plated onto 1.5% gelatincoated wells and grown in medium 199 (M199) (GIBCO BRL, Gaithersburg, MD) with 20% fetal bovine serum (FBS) (GIBCO BRL), endothelial cell growth supplement (100 g/ml) and heparin (50 U/ml). HUVECs were used between passage 1 and 5. Human microvascular (HM) ECs of dermal origin were purchased from Clonetics Corp. (San Diego, CA), grown in EBM medium containing human epidermal growth factor (10 ng/ml), hydrocortisone (10 mg/ml), 5% FBS and 0.4% bovine brain extract (Clonetics Corp.). HMECs were used between passages 4 and 6.
L6 cells, a methyl cholantrene-transformed rat myoblast cell line purchased from American Type Culture Collection (Rockville, MD), were grown in DME ϩ 10% FBS and used between passages 6 and 8. Human vascular smooth muscle cells (SMCs) were isolated from segments of internal mammary arteries obtained at bypass surgery (St. Elizabeth's Medical Center) and grown as previously described (25) . SMCs were used between passages 3 and 5.
Northern blot analysis. Extraction of total RNA and Northern blot analysis were performed as previously reported (17) . The DNA probes were: for human KDR, a 709-bp EcoRI-HindIII fragment (gift of B.Terman, American Cyanamid, NJ); for human flt-1 , a 417-bp KpnI-HindIII fragment (gift of L. T. Williams, UCSF, CA); for human VEGF, a 675-bp EcoRI-BglII fragment (gift of N. Ferrara, Genentech Inc., CA); for ␤ -actin, a 1.5-kb EcoRI fragment of plasmid HFBCC49, purchased from the American Type Culture Collection. Probes were radiolabeled using a random primed DNA labeling kit (Boehringer Mannheim, Indianapolis, IN) to specific activities of 1-10 ϫ 10 8 cpm/ g. Identification of functional VEGF receptors on HUVECs. To verify that functional VEGF receptors were present in ECs in our cultures, phosphorylated forms of KDR and flt-1 were identified. HUVECs were incubated overnight in M199 ϩ 1% BSA and stimulated for 10 min with VEGF (100 ng/ml). Lysis of cells, immunoprecipitation and Western immunoblot analysis were performed according to published methods (26) . Briefly, aliquots of protein extracts (1 mg) were incubated with an anti-phosphotyrosine monoclonal antibody (UBI, Lake Placid, NY) for 3 h at 4 Њ C, followed by incubation with Protein A-Sepharose beads for 40 min at 4 Њ C. Beads were washed with immunoprecipitation buffer followed by four washes with PBS (26) . Immunoprecipitates of tyrosine-phosphorylated proteins were separated by 8.75% SDS-PAGE and transferred to nitrocellulose filters. The membranes were immunoblotted with an affinity-purified anti-KDR rabbit polyclonal antibody (1:2000) (gift of B. Terman; American Cyanamid, Wayne, NJ) and an affinity-purified rabbit polyclonal anti-human flt-1 antibody (0.5 g/ml) (Santa Cruz Biotechnology, Santa Cruz, CA) for 3 h at room temperature. Blots were washed with 0.1% Tween 20-PBS (TPBS) for 1 h and incubated with a peroxidase-linked goat anti-rabbit antibody (1:10000) for 45 min. After extensive washing with TPBS and a final wash with PBS alone, immunoreactive bands were visualized using ECL reagent (Amersham Corp., Arlington Heights, IL).
Hypoxia. To expose cells to conditions of low oxygen tension, cell plates were arranged in air chambers (Billups-Rothenberg) constructed with inflow and outflow valves. A pre-analyzed air mixture (95% N 2 ϩ 5% CO 2 ; AIRCO) was infused into the air chambers at a flow rate of 3 liters/min for 15 min twice a day (17) . The pO 2 measured with a gas analyzer (278 Blood gas Systems, Ciba-Corning Diagnostics Corp.), reached a nadir of 35 mmHg in the culture medium about 6 h after the infusion was completed and persisted at 24 and 48 h.
Exposure of ECs to low oxygen tension. We investigated whether hypoxia could modify the expression of VEGF receptors on ECs. To this purpose HUVECs (four experiments) were exposed to low oxygen tension for 1, 4, 6, and 24 h. HMECs were exposed to hypoxia for 1, 3, 7, and 24 h. Control ECs were maintained in normoxia and evaluated at corresponding time points. Fresh HUVEC or HMEC culture medium or DME ϩ 1% BSA ϩ 1% FBS (5 ml/100 ml plate) were used for these experiments.
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I-VEGF binding to ECs exposed to direct hypoxia or control ECs was assessed as described below (binding assay and analysis).
Generation of hypoxia-conditioned medium by muscle cells. To determine if hypoxic cells, located in proximity to ECs in vivo, could influence VEGF receptor expression by production and/or release of soluble factor (s), ECs were treated in vitro with medium conditioned by hypoxic muscle cells. These experiments are referred to as "indirect" hypoxia. Rat myoblasts or human SMCs were maintained in hypoxia or normoxia for 4 d without medium change (DME ϩ 10% FBS; 2.5 ml/100 mm plate). Pooled media were then spun (3200 g , 10 min, 4 Њ C), sequentially passed through 0.45 and 0.2 m sterile filters, and used immediately or stored at Ϫ 80 Њ C for up to 1 wk. pH and lactic acid concentration (lactic dehydrogenase enzymatic assay; Smith Kline Clinical Laboratories, Waltham, MA) of normoxia-and hypoxia-CM were determined before treatment of ECs.
Treatment of ECs with muscle cell conditioned medium. Before each "indirect" hypoxia experiment, ECs were washed twice with PBS and starved overnight in DME ϩ 1% BSA ϩ 1% FBS, to maintain similar basal levels of receptor expression. HUVECs (four experiments) or HMECs (two experiments) were treated for 1, 4, 7, 16, 24, or 48 h with CM and VEGF binding to ECs determined as described below (binding assay and analysis). In two separate experiments, hypoxia-CM was serially diluted with normoxia-CM ( I-VEGF between 50 and 1600 pM were used. The binding medium was then aspirated, following which ECs were washed three times with ice-cold PBS ϩ 1% BSA, and lysed in 10 mM Tris, pH 7.4; 1 mM EDTA; 1% NP-40; 1 M leupeptin; 5 M aprotinin and 1 mM PMSF. Lysates were counted using a Beckman Gamma 5500B counter. Triplicate samples of each condition were obtained for each experiment. Non-specific binding was determined by competition with a 200-fold molar excess of nonradiolabeled VEGF. Specificity of binding was evaluated in preliminary experiments by addition of 100-fold molar excess of bFGF and PDGF-BB (Genzyme Corp., Cambridge, MA).
Nonlinear regression and Scatchard analysis were performed using Prism software (Graph-Pad Software, San Diego, CA). Statistical analysis was performed using ANOVA.
The number of cells/cm 2 was assessed by trypsinization and count of duplicate wells at 24 h. Cell number were compared by t test analysis.
Neutralizing antibodies. To establish the identity of putative factors responsible for the increased binding of 125 I-VEGF to human ECs, selected neutralizing antibodies were added independently to hypoxia-CM before treatment of ECs. A rabbit polyclonal anti-tumor necrosis factor ␣ (TNF-␣ ) antibody (Genzyme Corp.), was added at concentrations of 20 or 100 g/ml. A rabbit polyclonal pan-specific anti-transforming growth factor-␤ 1 (TGF-␤ 1) antibody (R & D Systems, Minneapolis, MN) was used at concentrations of 30 and 100 g/ ml. A mouse monoclonal anti-bFGF antibody (UBI, Lake Placid, NY) was used at concentrations of 1 and 20 g/ml. In all cases binding was assessed after incubation of HUVECs for 24 h.
To investigate the possibility that VEGF, previously shown to be upregulated in hypoxic myocytes (12, 13, 17), could cause homologous upregulation of its receptors, VEGF (100 ng/ml) or a high concentration of neutralizing goat polyclonal anti-VEGF antibody (R & D Systems, Minneapolis, MN) (200 g/ml) were added to normoxiaand hypoxia-CM respectively, and binding assessed at 24 h of treatment. Finally, we tested 125 I-VEGF binding to HUVECs treated for 24 h with normoxia-CM supplemented with lactic acid (10 mg/ml), a product of anaerobic glycolysis.
Results

Characterization of functional VEGF receptors in ECs.
We evaluated whether active KDR and flt-1 receptors were present in HUVECs. We could detect KDR mRNA ( ‫ف‬ 7 kb) in both HUVECs and HMECs (data not shown). The phosphorylated KDR receptor was identified as a band of ‫ف‬ 210 kD in immunoprecipitates of VEGF-treated, but not in control HUVECs (Fig. 1) . Flt-1 mRNA ( ‫ف‬ 7.5 kb) was detected in both HUVECs and HMECs (data not shown). However, using experimental conditions similar to those employed for KDR detection, we could not demonstrate a phosphorylated form of flt-1 receptor by immunoprecipitation of VEGF-treated HUVECs (data not shown).
Direct hypoxia does not modify (Fig. 2) . Similarly, exposure of HMECs to hypoxia had no detectable effect on 125 I-VEGF binding (data not shown).
Effects of hypoxia on muscle cells. Because hypoxic treatment did not directly modify 125 I-VEGF binding to ECs, we investigated whether hypoxic cells other than ECs could produce and/or release "factors" capable of upregulating the expression of VEGF receptors. To this purpose, we used two cell types of muscular lineage. Light microscopic examination of normoxic rat myoblasts at 4 d showed no evidence of distress or cell detachment; multinucleated and elongated myotubes were evident. In contrast, focal detachment of rat myoblasts was observed beginning at 48 h of hypoxic treatment. By day 4, detachment had extended to most of the plate surface, with only sporadic patches of cells still attached; this finding may represent the equivalent of necrosis in severely ischemic tissues.
However, 4 d of hypoxic treatment resulted in cellular elongation and evident network of stress fibers, but no detachment or necrosis of SMCs.
Medium conditioned by hypoxic myoblasts increases 125 I-VEGF binding to human ECs. Treatment of ECs with hypoxia-CM from rat myoblasts produced a significant increase in 125 I-VEGF specific binding to HUVECs (Fig. 3) and HMECs (Fig. 4) . Increased binding was evident at 4 h of treatment, peaked at 24 h ( P Ͻ .001, for HUVECs; P Ͻ 0.003, for HMECs) and declined slightly at 48 h ( Fig. 3 and 4) , although still remaining above binding levels achieved using normoxia-CM. Binding was specifically competed by addition of 200-fold molar excess of non-radiolabeled VEGF, but was not modified by addition of 100-fold molar concentrations of either bFGF or PDGF-BB (data not shown).
Scatchard analysis of HUVECs incubated with 125 I-VEGF concentrated to 50 pM or higher, indicated a single high affinity VEGF binding site. Nonlinear regression analysis of the data indicated a K d ϭ 260 Ϯ 51 pM in normoxia-CM and a K d ϭ 281 Ϯ 94 in hypoxia-CM, corresponding to the reported affinity constant of KDR receptor (8, 28) (Fig. 5 A ) . When the number of receptors/cell was calculated from Bmax values (10 pM, normoxia-CM versus 40 pM, hypoxia-CM), a 13-fold increase in KDR receptors present on the surface of HUVECs after treatment with hypoxia-CM was detected (normoxia-CM, 1.7 ϫ 10 3 receptors/cell; hypoxia-CM 23 ϫ 10 3 receptors/cell) (Fig. 5 B) . HUVECs were serum-starved overnight in M199 ϩ 1% BSA, then treated for 10 min with VEGF (100 ng/ml). Protein extracts (1 mg/sample) were immunoprecipitated with an antiphosphorylated tyrosine antibody, separated by 8.75% SDS-PAGE and transferred to membrane filters. Using an affinity-purified anti-KDR rabbit polyclonal antibody, a band ‫ف(‬ 210 kD) was detected in extracts of VEGF-stimulated, but not of control HUVECs, thus indicating presence of functional KDR receptors in HUVECs. Lane 1, control HUVECs; lane 2, HUVECs treated with VEGF (100 ng/ml) for 10 min. difference in pH of CM. Finally, as expected, lactic acid levels were remarkably different (0.6 mg/ml in normoxia-CM versus 9.5 mg/ml in hypoxia-CM). However, treatment of HUVECs with normoxia-CM supplemented with lactic acid (10 mg/ml) did not modify 125 I-VEGF binding to HUVECs (data not shown). These data exclude that increased binding of 125 I-VEGF to ECs treated with hypoxia-CM was due to variation in pH or lactic acid content of the medium. Medium conditioned by hypoxic myoblasts increases KDR mRNA levels in HUVECs. Levels of KDR mRNA (main band of ‫ف‬ 7 kb) were very low in HUVECs starved overnight in DMEM ϩ 1% BSA ϩ 1% FBS. Treatment of HUVECs with hypoxia-CM for 3 h increased KDR mRNA species, compared with baseline levels and with corresponding mRNA species in HUVECs treated for 3 h with normoxia-CM (Fig. 6) .
Medium conditioned by hypoxic smooth muscle cells increases
Addition of neutralizing antibodies to hypoxia conditioned medium does not attenuate 125
I-VEGF binding. To investigate whether known factors, likely to be produced and/or released by hypoxic myoblasts, could be responsible for the increased binding of 125 I-VEGF to ECs treated with hypoxia-CM, antibodies capable of neutralizing candidate growth factors bFGF, TGF-␤1 or TNF-␣ were added to the hypoxia-CM. bFGF is released by cells following cell damage and/or injury (29). TGF-␤1 modulates epidermal growth factor receptor expression (30) . TNF-␣ is produced by certain cell types in response to hypoxia (31) . However, neutralization of bFGF, TGF-␤1 and TNF-␣ did not affect 125 I-VEGF binding to ECs (Fig. 7) . Increased (17) and by myoblasts (13) in response to hypoxia. Therefore, VEGF present in hypoxia-CM could potentially cause upregulation of its own receptors. However, the addition of recombinant VEGF to the normoxia-CM did not affect 125 I-VEGF binding (Fig. 7) . Furthermore, addition of high dose of anti-VEGF neutralizing antibody to hypoxia-CM actually increased 125 I-VEGF binding to HUVECs (Fig. 8) . These results confirm that hypoxia-CM contains VEGF.
I-VEGF binding is not due to homologous regulation by VEGF. VEGF is produced by human SMCs
However, under the conditions tested, VEGF does not induce upregulation of its own receptors.
Discussion
VEGF is regarded as a fundamental mediator of hypoxiainduced angiogenesis. In vitro, the expression of this growth factor increases specifically in cells exposed to hypoxia (13, 17) . In vivo, increased VEGF expression occurs in a variety of pathological processes characterized by hypoxia-related neovascularization. For example, VEGF production is augmented during wound healing (9), as low oxygen tension occurs in the central part of a wound after disruption of local vasculature (22) . VEGF levels are increased during revascularization of ischemic, and therefore hypoxic, hearts (11) . In a recent report, increased VEGF expression has been detected in lungs of rats exposed to acute or chronic hypoxia (32). In addition, even in tumors, the production of VEGF appears not uniquely determined by the genetic program of neoplastic cells (14, 15, 33 ), but it is still inducible by hypoxic stimulation (20) . Figure 6 . Treatment of ECs with hypoxia-conditioned medium increases KDR mRNA levels. Northern analysis of KDR mRNA levels in HUVECs. Cells were maintained in HUVEC complete culture medium, serum starved overnight in DME ϩ 1% BSA ϩ 1% FBS (time 0), followed by treatment for 3 h with normoxia-or hypoxia-CM. Treatment with hypoxia-CM increased KDR mRNA levels. Levels of ␤-actin mRNA are shown for comparison of RNA loading in each lane. Two specific VEGF receptors, located on ECs, have been identified to date. They are KDR (6) and flt-1 (7), both tyrosine-kinases that autophosphorylate in response to VEGF treatment. Data from our laboratory using a rabbit ischemic hindlimb model indicated that systemic administration of VEGF protein selectively produces neovascularization in the ischemic limb (23) ; neither in the contralateral normal limb nor in any other organs were foci of neovascularization observed. Thus, in this experimental model, exogenously administered VEGF appears to be biologically "sequestered" and its activity limited uniquely to ischemic regions, perhaps due to local upregulation of its receptors. In vivo, increased expression of endogenous VEGF has been extensively documented in many pathologic tissues (9, 11, 13-15, 20, 32, 34, 35) . Moreover, increased expression of VEGF receptor mRNA species strictly limited to ECs of the same pathologic tissues (14, 15, 32, 34, 35) has been reported as well. These data suggest that hypoxia could affect angiogenesis (13, 14, 17, 22) not only by inducing the expression of VEGF (13, 14, 17) , a specific angiogenic growth factor, but also by causing a coordinated increase of the expression of VEGF/VPF receptors. However, whether the upregulation of VEGF receptors observed in vivo is promoted directly by hypoxia or secondarily, by local events induced by hypoxia remains to be determined. Accordingly, we investigated the possibility that hypoxia or hypoxia-dependent conditions could affect the specific binding of 125 I-VEGF to ECs. These experiments were performed on ECs in vitro, as hypoxic conditions are difficult to document and reproduce in vivo. Furthermore, we used human ECs obtained from two different vascular districts, as intrinsic differences exist among ECs from various vascular beds (36) .
We first evaluated binding of 125 I-VEGF to HUVECs and HMECs after exposure to low oxygen tension for various lengths of time, from 1 to 48 h. Although we cannot exclude with certainty that direct exposure of ECs to hypoxia might affect binding of 125 I-VEGF to ECs in vivo, our results indicate that low oxygen tension does not modulate such an event in vitro.
In a recent report, Thieme et al. reported that hypoxic stimulation of bovine retinal ECs induced a 50% increase in the level of VEGF receptors in this cell type (37) . The direct effect of hypoxia on VEGF receptors in bovine retinal ECs could reflect intrinsic differences between ECs from different vascular districts (36) . In particular, under basal conditions bovine retinal ECs possess three-fold more VEGF receptors than bovine aortic ECs (37). We had no opportunity to test 125 I-VEGF binding to retinal ECs, but we consistently obtained no detectable effect of hypoxia on 125 I-VEGF binding to the EC types tested.
To further evaluate the possibility of upregulation of VEGF receptors in response to conditions of low oxygen tension, we hypothesized that hypoxia might "indirectly" effect ECs. According to this hypothesis, "factor (s)" produced and/ or released by hypoxic cells different from ECs might regulate the expression of VEGF receptors on ECs. To test this hypothesis we initially assessed the binding of 125 I-VEGF to ECs treated with medium conditioned by L6 rat myoblasts maintained in hypoxia for 4 days.
We chose to use rat myoblast CM for various reasons. First, our observation of site-specific angiogenesis after systemic administration of VEGF was obtained using an experimental model of hindlimb ischemia (23) . This model is characterized by profound reduction of blood perfusion of the ischemic limb, with consequent hypoxia of muscular tissues. L6 rat myoblasts, transformed cells of muscular lineage, can be used to generate adequate volumes of CM. The treatment of ECs with medium conditioned by rat myoblasts in hypoxia for 4 d, caused a threefold increase of 125 I-VEGF specific binding. Such increase was consistently obtained when either HUVECs or HMECs were tested, and was maximal after 24 h of stimulation.
Because L6 rat myoblasts are a transformed cell line, we also tested CM obtained from non-transformed SMCs. These cells were isolated and grown from apparently healthy internal mammary arteries obtained at coronary artery bypass surgery. Microscopic examination of segments from similarly obtained arteries showed no apparent sign of abnormality. SMCs exposed to hypoxia for 4 d were intact and showed no signs of necrosis. Medium conditioned by hypoxic SMCs induced a significant increase of 125 I-VEGF binding to HUVECs. Therefore, we conclude that products released by cells undergoing necrosis as a consequence of severe hypoxia are not necessary for induction of VEGF receptor upregulation in ECs treated with hypoxia-CM. Furthermore, these data suggest the existence of a regulatory mechanism, common to transformed and non-transformed cells, which might coordinate angiogenesis under hypoxic conditions.
We could not detect a functional flt-1 receptor in HUVECs. Bikfalvi et al. was concentrated to 50 pM or higher, we could regard the contribution of the flt-1 receptor to 125 I-VEGF binding as negligible. We therefore assessed binding at concentrations of 125 I-VEGF Ն 50 pM, as flt-1 receptors appeared to be saturated at these concentrations.
We identified a functional KDR receptor in HUVECs. Moreover, the K d of the high affinity receptor species detected using 125 I-VEGF concentrated to 50 pM or higher conformed to K d values of KDR receptor previously reported by others (8, 28) . Furthermore, an increase of KDR mRNA levels was detected in HUVECs treated for 3 h with hypoxia-CM, as compared to KDR mRNA levels of HUVECs treated for the same time with normoxia-CM. Such an increase suggests that new synthesis of the receptor might be occurring, in conjunction with mobilization of preformed receptors from the cellular pool.
Under the conditions tested, Scatchard analysis of 125 I-VEGF binding indicated no substantial change in affinity of the KDR receptor in HUVECs treated with rat myoblasts medium conditioned either in normoxia or hypoxia. Thus, increased binding observed using hypoxia-CM was due to a 13-fold increase in the number of KDR receptors. Heldin and coworkers (8) have recently demonstrated that VEGF-induced effects on ECs in vitro are mediated via KDR receptors. Moreover, Park et al. have reported that placenta growth factor (PlGF), a member of the VEGF family of growth factors, binds to flt-1 , but not to KDR receptors (38) . Treatment of ECs with PlGF elicited no mitogenic or permeability-enhancing activity. However, PlGF was able to potentiate the biological effects of low doses of VEGF both in vitro and in vivo, probably by displacing VEGF bound to flt-1, and therefore increasing VEGF availability to the more relevant flk-1/KDR receptors (38) . Studies conducted in vivo using a dominantnegative mutant of flk-1, the mouse homologue of KDR receptor, also have emphasized the fundamental role of flk-1/KDR in VEGF induced angiogenesis (39) . Finally, flk-1/KDR temporally and spatially correlates with VEGF expression during development, suggesting a major role of this ligand-receptor system in vasculogenesis and angiogenesis (40) . These data strongly suggest a relevant role of KDR in mediating VEGF biological effects. We found that increased binding of The particular component of hypoxia-CM responsible for increased binding of 125 I-VEGF to ECs remains to be identified. Treatment of HUVECs with hypoxia-CM diluted with normoxia-CM caused diminished binding compared to treatment with undiluted hypoxia-CM; hypoxia-CM diluted to 25% with normoxia-CM produced no appreciable difference in binding compared to normoxia-CM alone. bFGF potently synergizes with VEGF in inducing angiogenesis in vitro (41, 42) . Such synergism could be due to an upregulation of VEGF receptor number by bFGF. Although bFGF expression is not induced by hypoxia (17) , this growth factor can be released as a consequence of cell damage (29) or mobilization from deposits in the extracellular matrix (43) . TNF-␣ is an indirect angiogenic growth factor (44), specifically induced by hypoxic stimulation (22) . TGF-␤1, an indirect growth factor itself, can also modulate the number of epidermal growth factor receptors on certain cell types (30) . Therefore we tried to specifically neutralize these candidate growth factors possibly present in the hypoxia-CM. In no case, however, did the addition of neutralizing antibodies diminish the increase in 125 I-VEGF binding due to hypoxia-CM.
Finally, hypoxic treatment of muscle cells induces expression of VEGF itself (13, 17) . As homologous upregulation of receptors by their specific ligands has been previously described for certain growth factors (45), we investigated the possibility that VEGF present in hypoxia-CM could upregulate its own receptors. Again, the addition of VEGF to normoxia-CM did not modify 125 I-VEGF binding. Moreover, the addition of an anti-VEGF neutralizing antibody to hypoxia-CM further increased the 125 I-VEGF binding to ECs. These data therefore exclude the possibility of homologous upregulation of the receptors by VEGF itself.
These data suggest that a "factor" present in hypoxia-CM might be important in modulating VEGF specific binding to ECs. Further experiments will establish whether hypoxic cells (a) release a "factor capable of increasing the expression of VEGF receptors; (b) down-regulate an inhibitor of VEGF receptor expression normally produced by cells; or (c) release a "factor" capable of blocking a putative VEGF receptor inhibitor normally produced by cells.
Our results suggest that paracrine mechanisms initiated by hypoxia can operate to induce angiogenesis in ischemic tissues. Hypoxic cells different from ECs can both produce VEGF, as previously demonstrated by us and others, and also produce soluble factors capable of upregulating the expression of KDR, a functional VEGF/VPF receptor, on ECs. It is intriguing that this paracrine mechanism may operate in vivo not only in hypoxic areas of tumors but also in nonneoplastic conditions, such as in ischemic peripheral vascular disease.
